GPhA's New CEO Ralph Neas Brings Health Reform Advocacy Experience
This article was originally published in The Pink Sheet Daily
Executive Summary
After 14-month vacancy, GPhA fills its top post with National Coalition on Health Care CEO Ralph Neas, who offers coalition-building skills and long background in civil rights political work.
You may also be interested in...
GPhA’s Goals For 2013: Smooth GDUFA Implementation, Workable Biosimilar Pathway
The generic drug trade association’s cross-cutting priorities are the result of an extensive strategic planning process, CEO Ralph Neas says; the group is planning outreach to Congress and the executive branch to highlight the role generic drugs can play in helping to address the nation’s fiscal problems.
Deficit Super Committee Inaction May Be Best Scenario For Biopharma
It may be a best-case scenario for the biopharmaceutical industry if the Joint Select Committee on Deficit Reduction is unable to produce a proposal by Thanksgiving to cut the federal deficit by at least $1.2 trillion over 10 years.
Patent Reform: Senate May Amend Two Provisions In House Bill
The Senate will vote on whether to limit debate on the House-passed patent reform bill when it reconvenes on Sept. 6. Senate Majority Leader Harry Reid, D-Nev., made a motion for the cloture vote before the August recess in hopes of getting a final bill through Congress quickly.